AR201

FAQ for Palforzia, the First FDA Approved Therapy for Food Allergy

Dave Bloom - 2019/09/15

What it is, what it treats, who it is for, how it is used, et al.

Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for...

News Wire ~ 3rd Party Press Release - 2019/08/21

AR201 is the second development program that Aimmune is advancing to phase 2 using its Characterized Oral Desensitization ImmunoTherapy (CODIT™) platform.

Aimmune to Begin Phase 2 Trials of Egg Allergy OIT Candidate

News Wire ~ 3rd Party Press Release - 2018/12/20

AR201 for Egg Allergy Phase 2 Initiation Planned for 2019.

Established in 2011, SnackSafely.com provides straightforward, actionable information to help improve the lives of the estimated 32 million people in the US suffering with food allergies.

We strive to eliminate anaphylaxis by leveraging our on-line properties to educate, advocate, and connect the allergic community with products and services that help toward achieving this goal.

Our blog covers topics of interest to the food allergy community including news reports; ongoing research, clinical studies, trials and progress toward treatment and cure; general advocacy; and advice regarding food safety and school policies.

Please see our Terms of service and Privacy Policy.

SnackSafely.com, PO Box 141, Hillsdale, NJ 07642

Tag: AR201

FAQ for Palforzia, the First FDA Approved Therapy for Food Allergy

Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for...

Aimmune to Begin Phase 2 Trials of Egg Allergy OIT Candidate